How BPC-157 is proposed to work: the mechanism, in plain language

BPC-157 has spent thirty-odd years collecting mechanisms. Read the marketing and you’ll find a peptide credited with new blood vessel growth, calmer inflammation, faster tendon repair, a settled gut, and a quiet shield over half the things that go wrong in a body.

The actual mechanism is narrower than the marketing makes it sound, sits almost entirely in animal models, and turns on two specific biochemical pathways.

The structural fact people get wrong first

BPC-157 is not BPC. That sounds like a pedantic distinction. It changes how the molecule should be thought of.

Body protection compound — BPC — is a large protein found in gastric juice. In the early 1990s, a research group at the University of Zagreb led by Predrag Sikirić isolated a specific stretch of that protein and found the fragment, on its own, kept showing tissue-protective activity in animal models. That fragment — fifteen residues of the larger BPC — is what gets sold as BPC-157.

Shorthand: BPC-157 is a pentadecapeptide, a fifteen-amino-acid sequence — the 15-residue partial sequence of body protection compound, not the full protein. Anything sold as BPC on a research-chemical site is almost certainly BPC-157. The two are not interchangeable.

The two pathways the mechanism actually rests on

The proposed mechanism comes down to two things: angiogenesis and the nitric oxide pathway. Everything else — tendon repair, mucosal protection, the long list of organ systems the literature catalogues — is framed by the original research group as downstream of those two.

Angiogenesis is the growth of new blood vessels. When tissue is damaged, the body pushes blood into it to bring oxygen, nutrients, and the cellular crew that does the repair work. Tendons in particular have poor blood supply on their own, which is part of why they heal so slowly. A peptide that promotes new vessel growth at an injury site is, mechanistically, plausibly helpful. A 2025 narrative review in Pharmaceuticals by Józwiak and colleagues catalogues the angiogenic effects reported across decades of animal work.

Nitric oxide — written NO — is a short-lived signalling molecule the body uses to relax blood vessels, regulate blood flow, and coordinate cellular housekeeping. The Sikirić group’s framing, defended in a 2025 comment in Pharmaceuticals, is that BPC-157 acts on the NO pathway to maintain protective vascular and cellular function, and that the effects across so many tissue types come from NO signalling being everywhere.

Angiogenesis plus NO, with the rest as consequence — that’s the closest thing the BPC-157 literature has to a coherent mechanism story. It is a hypothesis, not a conclusion. The mechanism is proposed in animal models; human mechanistic data doesn’t exist.

Cytoprotection, not tumour induction — the open argument

The same mechanism that makes BPC-157 interesting for repair is the one that should give a careful reader pause. Tumours need blood vessels. A peptide that grows new ones, in principle, raises a fair cancer-relevance question.

The published 2025 Pharmaceuticals exchange on this is the most direct version of the argument anyone has put on the record. Józwiak and colleagues catalogued the angiogenic mechanism without resolving the question. Sikirić’s group responded, arguing that decades of animal work show cytoprotection — the protection of normal cells — rather than tumour induction. Both positions are defensible from the animal data. Neither has been settled with human evidence.

The honest version: cancer-relevance is an open question, the active researchers disagree, and there’s no human data either way.

What the mechanism work actually shows — and doesn’t

Almost everything we have on BPC-157’s mechanism comes from animal models. Rats are the dominant species. The endpoints are usually histology — looking at the tissue under a microscope — plus functional readouts in injured animals: a tendon that bounces back, a stomach lining that resists damage, a wound that closes faster. The signal across that body of work is consistent enough that the 2025 systematic review in HSS Journal by Vasireddi and colleagues describes BPC-157 as an emerging candidate in orthopaedic sports medicine, and a 2026 review by Matek and colleagues in Pharmaceuticals (Basel) extends the picture to tendon, ligament, and muscle injury at the junctions where those tissues meet bone.

Both reviews are honest about what the underlying literature actually is. Volume of animal evidence. Limited human evidence. A mechanism story that is plausible and coherent in the model systems and untested in people.

What the work has not done in humans: a single published, controlled mechanism trial in an injured patient population. No human pharmacokinetic data on where the peptide actually goes after injection. No published demonstration that the angiogenic and NO-pathway effects shown in rats happen the same way in a person. The mechanism is a hypothesis carried by animal experiments.

What sits in the human file

This is the short paragraph. The first registered controlled human trial of BPC-157 in an injury indication — a Phase 2 randomised, placebo-controlled study of BPC-157 for acute hamstring strain (NCT07437547) — began recruiting in 2026. No results yet.

That single trial, recruiting, with nothing yet to read out, is the entire near-term human mechanism evidence. The rest of the human file is two small uncontrolled pilots in unrelated indications — neither testing mechanism, neither in an injury population — that we covered in detail in the BPC-157 injury-recovery deep-dive.

The regulatory positioning

BPC-157 is among the bulk drug substances on the FDA Pharmacy Compounding Advisory Committee’s July 23, 2026 docket per Federal Register notice 2026-07361, with the FDA-reviewed use listed as ulcerative colitis — a mucosal-protection indication that matches the original gastric-juice biology the compound was isolated from, not the tendon-repair use the off-label market sells.

That distinction matters for mechanism conversations specifically. The compound is going in front of an advisory committee for a gut-mucosa indication. The mechanism review the FDA does will weigh the angiogenic-and-NO story in that context, not in the tendon-repair context that drives demand. We covered the mechanics of how a PCAC review works in What is the PCAC.

What would actually settle the mechanism question

A human pharmacokinetic study — how much of an injected dose actually reaches the tissues, and how long it stays.

Independent labs reproducing the angiogenesis-and-NO-pathway results outside the Sikirić group. Three decades of mostly one-group work is a real volume of evidence, but mechanism stories that survive only inside the discovering lab tend to look different once an outside team tries to reproduce them.

A human trial with mechanistic readouts, not just clinical endpoints. The hamstring strain trial currently recruiting will deliver a controlled efficacy signal, which is itself a first. Tissue imaging, vascular markers, NO-pathway biomarkers alongside that would close the loop.

A clean answer on the cancer-relevance question. The Józwiak–Sikirić exchange points exactly at the experiment that would settle it.

The mechanism story is plausible. The animal work is consistent enough to be worth taking seriously. The human mechanism file is essentially empty, and the first trial that might start filling it is recruiting now. That’s where the evidence actually sits.

The honest version of a BPC-157 protocol is the one a physician writes against an FDA-reviewed indication, dispensed by a US-licensed compounding pharmacy, with a hamstring trial that has actually read out behind it. Wolverine Health is being built to be that version. Join the waitlist if you want a heads-up the moment any of those pieces — the trial, the vote, the regulated supply — actually land.